N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=43 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
Osteosarcoma · Malignant Fibrous Histiocytoma (MFH) of Bone
Primary: Number of Participants With Unacceptable Toxicity — 0; 0; 0; 0 participants
Phase 3 N=1,334 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
Localized Osteosarcoma · Metastatic Osteosarcoma
Primary: Event-free Survival (EFS) — 74; 77; 55; 53 Percentage EFS — p=0.214
Phase 2 N=56 Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Metastatic Osteosarcoma · Recurrent Osteosarcoma · Refractory Osteosarcoma
Primary: Disease Control Rate (Cohort I) — 1 participants
Phase 2 N=32 Chemotherapy for Patients With Osteosarcoma
Osteosarcoma
Primary: Percentage of Participants With Tumor Response — 3.1; 0; 3.1; 15.6 percentage of participants
Phase 2 N=11 Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
Sarcoma
Primary: Tumor Response — 10 participants
Phase 1 N=23 Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
Solid Tumor · Osteosarcoma
Primary: Dose Escalation Part: Number of Dose-Limiting Toxicities (DLTs) at Each Dose Level on Cycle 1 — 0; 2 Number of DLTs
Phase 2 N=49 Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
Metastatic Cancer · Sarcoma
Primary: Status of FAS Ligand in Pre-chemotherapy Sample — 7; 5; 1; 1 participants
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Phase 2 N=22 Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Recurrent Osteosarcoma
Primary: Disease Control Success — 3 Participants
Phase 1 N=24 Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Sarcoma
Primary: Limiting Toxicity — 1; 1; 3; 2 participants
Phase 2 N=18 A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
Osteosarcoma
Primary: Response Rate — 0 percentage of participants
Phase 2 N=54 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Sarcoma
Primary: Objective Response Rate — 6; 5; 14 participants
Phase 2 N=19 Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
Osteosarcoma Metastatic
Primary: The Study Medication Was to be Considered Effective if the Population Response Rate Was Found to be Greater Than 20% and Individuals Who Demonstrated a CR or PR or Whose…
Phase 2 N=19 Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
Recurrent Osteosarcoma
Primary: Disease Control Success — 0 participants
N/A N=9 (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 2 N=5 BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Phase 2 N=40 Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma
Osteosarcoma
Primary: Radiographic Response — 21; 5; 5; 3 participants
Phase 2 N=12 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Ewing's Sarcoma
Primary: Objective Response Rate of Olaparib — 0 Participants
Phase 2 N=80 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Sarcoma
Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants
Phase 2 N=16 Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
Metastatic Soft Tissue Sarcoma
Primary: Part 2: Radiologic Progression-free Survival (PFS) — 18.7; 24.1 weeks — p== 0.6562
Phase 2 N=18 Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Sarcoma
Primary: Maximum Tolerated Dose (MTD) of Ra-223 Dichloride in Osteosarcoma — 100; 100 kBq/kg
Phase 2 N=20 SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Metastatic Leiomyosarcoma
Primary: Response Rate (Per RECIST 1.1) — 1 Participants
Phase 2 N=20 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Bone Cancer · Chondrosarcoma · Clear Cell Sarcoma of the Kidney
Primary: Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response — 0 participants
Phase 2 N=147 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 2 N=52 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Phase 2 N=97 ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Soft Tissue Sarcoma
Primary: Progression-free Survival (PFS) (Cohort 1 Only) — 5.0597 months
Phase 2 N=41 Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Metastatic Malignant Neoplasm in the Lung · Metastatic Osteosarcoma · Recurrent Osteosarcoma
Primary: Disease Control — 11 Participants